HF
ABOS icon

HRT Financial’s Acumen Pharmaceuticals ABOS Stock Holding History

HRT Financial’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,162
Closed -$31K – 4062
2026
Q1 		$31K Buy
+13,162
New +$33.6K ﹤0.01% 3522
2025
Q4 		– Sell
-14,014
Closed -$23K – 3096
2025
Q3 		$23K Sell
14,014
-17,413
-55% -$24.1K ﹤0.01% 2689
2025
Q2 		$36K Buy
+31,427
New +$33.8K ﹤0.01% 2345
2024
Q2 		– Sell
-105,117
Closed -$425K – 2129
2024
Q1 		$425K Buy
+105,117
New +$396K ﹤0.01% 1343
2023
Q2 		– Sell
-43,115
Closed -$175K – 2359
2023
Q1 		$175K Buy
43,115
+22,443
+109% +$117K ﹤0.01% 1951
2022
Q4 		$111K Buy
+20,672
New +$139K ﹤0.01% 2047
2022
Q1 		– Sell
-81,917
Closed -$553K – 3000
2021
Q4 		$553K Buy
+81,917
New +$900K ﹤0.01% 1672

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

HRT Financial's ABOS Position: Q2 2026 in Review

HRT Financial sold out of Acumen Pharmaceuticals (ABOS) in Q2 2026, closing a stake of 13,162 shares — an estimated $31K sold.

HRT Financial first reported a position in ABOS in Q4 2021 and held it in 7 quarters. The position peaked at $553K in Q4 2021. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • HRT Financial reported no remaining Acumen Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 13,162 Acumen Pharmaceuticals shares in Q2 2026, an estimated $31K.
  • HRT Financial first reported a position in Acumen Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • HRT Financial's Acumen Pharmaceuticals position peaked at $553K in Q4 2021.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.